What Is Reta? Retatrutide, Peptides & the GLP-1 Triple Agonist Explained
Reta is the name many people online use for retatrutide, an investigational peptide designed to act on three hormone receptors: GIP, GLP-1 and glucagon.
Quick Answer: What Is Reta?
“Reta” usually refers to retatrutide. Retatrutide is an investigational peptide that activates the GIP, GLP-1, and glucagon receptors. It includes GLP-1 receptor activity, but it is more accurately described as a triple receptor agonist rather than simply a GLP-1 medication.
Retatrutide remains investigational and is not currently an FDA-approved medication.
Is Reta a Peptide?
Yes. Retatrutide is a peptide.
Published clinical research describes retatrutide as a single peptide with activity at the GIP, GLP-1, and glucagon receptors.
A peptide is a chain of amino acids. Many naturally occurring hormones in the body are peptides, and peptide-based medicines can be designed to interact with specific receptors.
However, the fact that retatrutide is a peptide does not mean products advertised online as “Reta peptide” are approved retatrutide medicines.
Is GLP-1 a Peptide?
Yes. GLP-1 stands for glucagon-like peptide-1.
GLP-1 is a naturally occurring peptide hormone. A GLP-1 receptor agonist is a substance designed to activate the GLP-1 receptor.
This distinction matters because retatrutide does more than activate the GLP-1 receptor.
Is Retatrutide a GLP-1?
Retatrutide has GLP-1 receptor agonist activity, but describing it only as “a GLP-1” leaves out two of its three targets.
| Receptor | Retatrutide activity |
|---|---|
| GIP receptor | Yes |
| GLP-1 receptor | Yes |
| Glucagon receptor | Yes |
That makes retatrutide a GIP/GLP-1/glucagon triple receptor agonist.
For comparison, semaglutide primarily targets the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors.
Compare retatrutide and tirzepatide →
Is Reta a GLP-1 or GLP-3?
Retatrutide is not scientifically classified as “GLP-3.”
The phrase “GLP-3” is sometimes used informally online because retatrutide acts at three receptors. But the three targets are not three GLP receptors.
- GIP
- GLP-1
- Glucagon
The more accurate description is triple hormone receptor agonist or triple agonist.
Bottom line: Retatrutide activates the GLP-1 receptor, but it also activates GIP and glucagon receptors. “GLP-3” is an informal nickname, not the scientific classification.
Why Is Retatrutide Different From Other GLP-1 Drugs?
The easiest way to understand what makes retatrutide different is to look at the receptors targeted by several well-known medications.
| Medication | Receptor activity |
|---|---|
| Semaglutide | GLP-1 |
| Tirzepatide | GIP + GLP-1 |
| Retatrutide | GIP + GLP-1 + glucagon |
This three-receptor design is the main reason retatrutide is described as a triple agonist. Having three receptor targets does not automatically mean a medication is better for a particular person. Retatrutide is still being studied, and individual treatment decisions belong with a licensed healthcare provider.
Clinical studies have investigated retatrutide in people with obesity, type 2 diabetes, and obesity-associated conditions. Trial findings describe results across groups of participants and cannot predict what an individual person will experience.
Is Retatrutide FDA Approved?
No. Retatrutide remains an investigational medication and is not currently approved by the U.S. Food and Drug Administration.
Reta Support does not sell, source, prescribe, compound, or provide access to retatrutide or other medications.
Why Do People Call Retatrutide “Reta”?
Long medication names often develop shortened names in everyday online conversations, and Reta has become common shorthand for retatrutide.
Reta Support uses familiar search language to make educational information easier to find while maintaining an important boundary: this site is an educational tracking and personal organization resource, not a medication seller or dosing service.
What Can You Track During a GLP-1 Journey?
People often forget details between appointments. Personal tracking can help organize observations and questions for discussions with a licensed healthcare provider.
RetaTracker can help organize:
- Weight and progress trends
- Food noise and appetite observations
- Symptoms and GI notes
- Hydration
- Protein awareness
- Mood and energy
- Injection notes
- Non-scale victories
- Questions for a healthcare provider
Track the week — not just the weight.
RetaTracker helps you keep your GLP-1 observations organized in one place so you have a clearer record of what happened between visits.
Frequently Asked Questions About Reta
What Is Reta?
Reta is commonly used as a shortened name for retatrutide, an investigational triple hormone receptor agonist.
Is Reta the same thing as retatrutide?
When people are discussing GLP-1 and weight-management medications, Reta generally refers to retatrutide.
Is Reta a peptide?
Yes. Published clinical research describes retatrutide as a single peptide that activates GIP, GLP-1, and glucagon receptors.
Is retatrutide a GLP-1?
Retatrutide activates the GLP-1 receptor, but it also activates GIP and glucagon receptors. Triple receptor agonist is therefore a more complete description.
Is Reta a GLP-1 or GLP-3?
Retatrutide includes GLP-1 receptor activity, but “GLP-3” is not its scientific classification. It is a GIP, GLP-1, and glucagon triple receptor agonist.
Is retatrutide FDA approved?
No. Retatrutide remains investigational and is not currently FDA approved.
Can you buy retatrutide from Reta Support?
No. Reta Support does not sell, source, prescribe, recommend, compound, or provide access to retatrutide.
Does RetaTracker tell users how much retatrutide to take?
No. RetaTracker is an educational tracking and personal organization tool. It does not provide dosing, titration, prescribing, or treatment recommendations.
Key Takeaway
In simple terms, Reta is shorthand for retatrutide. Retatrutide is a peptide and an investigational triple receptor agonist targeting GIP, GLP-1, and glucagon receptors. It includes GLP-1 receptor activity but is not scientifically classified as “GLP-3.”
Reta Support focuses on educational tracking, weekly pattern awareness, and helping people organize questions for conversations with licensed healthcare providers.
Sources and Further Reading
- Eli Lilly — What to Know About Retatrutide
- U.S. FDA — Concerns With Unapproved GLP-1 Drugs
- PubMed — Retatrutide Phase 2 Clinical Research
- New England Journal of Medicine — Retatrutide for Obesity
Written by Dawn Feldpausch, LCSW
Founder of Reta Support
Last reviewed: September 26, 2026
Content type: Educational retatrutide information
Reta Support provides educational tracking tools and personal organization resources only. It does not provide medical advice, diagnosis, treatment, prescribing, dosing guidance, medication sourcing, or emergency services. Always follow the guidance of your licensed healthcare provider.